The global cell therapy growth factor market size was valued at USD 5.34 billion in 2025 and is projected to grow from USD 5.71 billion in 2026 to USD 9.74 billion by 2034, registering a CAGR of 6.91% during the forecast period (2026-2034). North America dominated the cell therapy growth factor market with a share of 36.73% in 2025.
Cell therapy growth factors are biologically active proteins and signaling molecules used to regulate cell proliferation, differentiation, survival, migration, and maturation during cell expansion, and therapeutic development. They are primarily classified under HSN/HS Code 3002.59 (Other human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; other blood fractions and immunological products) and SIC Code 2836 (Biological Products, Except Diagnostic Substances).
The cell therapy growth factor market demand is driven by the expansion of cell & gene therapy research, development of stem cell-based therapies, and investments in regenerative medicine. The adoption of serum-free and chemically defined cell culture systems, improvements in recombinant protein production, and the need for high-quality also supports the cell therapy growth factor market growth.
Download a Free Sample To learn more about this report,
Shift Toward Serum-Free and Chemically Defined Culture Systems
The use of controlled, animal-origin-free culture conditions is increasing demand for defined growth-factor formulations in cell therapy development and manufacturing. This transition is reducing variability associated with undefined biological components while improving process consistency across cell expansion workflows. For example, Gibco CTS products from Thermo Fisher Scientific include serum-free and xeno-free media systems designed for cell therapy manufacturing.
Adoption of Cell-Type-Specific Growth Factor Combinations
Complex stem-cell and immune-cell manufacturing leads to higher demand for growth-factor combinations tailored to specific cell types, stages of expansion, and differentiation protocols. This shift is moving growth factors from standardized individual reagents toward application-specific formulations that support targeted cell behavior and therapeutic performance. For example, STEMCELL Technologies offers defined cytokine and growth factor combinations for applications including hematopoietic stem cells and pluripotent stem-cell differentiation.
Supply chain disruptions are expected to have a moderate impact on the cell therapy growth factor market share, given its exposure to fluctuations in recombinant protein production inputs, cell culture media components, bioreactor supplies, specialized raw materials, and international transportation costs. The market is expected to experience a K-shaped recovery, as established growth factor manufacturers can stabilize production faster. The market is expected to grow at a CAGR of 6.91%, but prolonged supply chain constraints could lower this by 1.5 percentage points, resulting in short-term growth of around 5.41%. As supply conditions normalize, the cell therapy growth factor market growth is expected to gradually return to 6.91%.
The cell therapy growth factor market forecasts investment/funding directed toward recombinant growth factor production, animal-origin-free cytokines, cell-culture proteins, and technologies supporting stem cell and cell therapy applications. In September 2026, Qkine secured over USD 1.6 million in funding from CPI Enterprises, EverQuest Capital Partners, Parkwalk Advisors, and EMV Capital. The funding will expand growth-factor production, R&D, U.S. operations, and cell therapy-grade manufacturing.
Higher Reliance on Recombinant Cytokines and Adoption of Advanced Cell Therapies Drives Market
Demand for recombinant cytokines is increasing as cell therapy developers require more consistent inputs for cell expansion, activation, and differentiation. The preference for defined and reproducible culture components supports demand for recombinant alternatives over variable biological materials.
The expanding clinical use of advanced cell therapies is creating additional demand for specialized culture inputs used during cell processing and expansion. FDA reported that CBER had approved close to 50 cell and gene therapies over the previous decade as of January 2026, indicating a growing base of commercial and late-stage therapies requiring scalable manufacturing inputs.
Dependence on Specialized Cold Chain Infrastructure and Limited Shelf Stability Restrain Market Expansion
Specialized storage and transportation requirements increase handling complexity for temperature-sensitive growth factors used in cell therapy workflows. Shorter stability windows for certain protein formulations can increase product loss and complicate inventory planning, particularly for smaller laboratories. These requirements can limit adoption where validated cold chain infrastructure is unavailable or costly.
Limited shelf stability of certain protein-based growth factors increases the risk of potency loss during storage and transportation. Strict temperature control and defined storage conditions can increase handling requirements and product wastage for laboratories and cell therapy manufacturers.
Expansion of Organoid-Based Cell Models and Adoption of Organ-on-Chip and Microphysiological Systems Offer Growth Opportunities
Organoid developers can use specialized growth factors to control cell proliferation, differentiation, and tissue-specific development in complex three-dimensional models. This creates revenue avenues for suppliers offering application-specific cytokines, recombinant proteins, and defined growth-factor combinations. Companies can benefit through specialized products for organoid culture and differentiation workflows.
Organ-on-chip developers can incorporate growth factors into controlled cellular environments that reproduce selected tissue functions for research and drug-development applications. This creates opportunities for growth factor suppliers to provide customized formulations compatible with microfluidic systems and tissue-specific models.
The fibroblast growth factor segment accounted for a share of 18.7% in 2025, supported by its broad use in cell proliferation, stem cell maintenance, differentiation, and tissue engineering applications. Its established role across multiple cell culture workflows supports its leading position within growth factor types.
The brain-derived neurotrophic factor segment is expected to grow at a CAGR of 7.83% during the forecast period, fueled by its use in neuronal cell survival, differentiation, and neuroregenerative research. The increasing application of BDNF in neurological cell models and regenerative medicine is supporting its expansion.
Request Customizationto receive a tailored report.
CAR-T dominated the cell therapy platform, accounting for a share of 28.6% in 2025. This dominance is led by the established use of cytokines and growth factors during T-cell activation, expansion, and differentiation workflows.
TIL therapy is projected to grow at a CAGR of 9.18% during the forecast period, propelled by the use of growth factors and cytokines to support lymphocyte expansion and functional maintenance. TIL-based workflows require controlled ex vivo expansion conditions, creating opportunities for specialized growth-factor formulations.
In 2025, oncology dominated the application segment with a share of 35.2%, supported by the extensive use of cell-based approaches in cancer research and therapeutic development. Growth factors and cytokines play an important role in immune-cell expansion and functional characterization across oncology-related cell therapy workflows.
Neurology is anticipated to expand at a CAGR of 8.04% during the forecast period, fueled by the use of growth factors in neuronal differentiation, neuroprotection, and regenerative research. Growth factors such as BDNF and NGF are particularly relevant to neuronal cell culture and tissue-specific model development.
Biopharmaceutical companies accounted for a dominant share of 44.3% in 2025, supported by their extensive involvement in cell therapy development, clinical manufacturing, process optimization, and commercialization activities. Their broad use of growth factors across research and production workflows supports their leading end-user position.
CDMOs are anticipated to grow at a CAGR of 8.15% during the forecast period, driven by increasing involvement in outsourced cell therapy development and manufacturing activities. Their role across process development, scale-up, and clinical manufacturing creates recurring requirements for standardized growth factors and cytokines.
Speak to an Analystto discuss market opportunities.
The North American cell therapy growth factor market accounted for a dominant share of 36.73% in 2025.
FDA issued guidance allowing greater flexibility in chemistry, manufacturing, and controls requirements for cellular and gene therapies, with the aim of expediting product development and supporting patient access. These developments create opportunities for suppliers of recombinant growth factors and cytokines used to support cell proliferation, viability, differentiation, and expansion in research, clinical trials, and commercial cell therapy manufacturing.
Canada's biomanufacturing strategy emphasizes stronger links between research, clinical development, manufacturing, and commercialization. National Research Council is expanding capabilities that connect early-stage research with larger-scale production. These developments are expected to create additional applications for standardized cell culture supplements, cytokines, recombinant proteins, and growth factors within automated cell manufacturing workflows.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cell therapy growth factor market is expected to grow at CAGR of 8.37% during the forecast period, showcasing the fastest growth.
China’s expanding cell and gene therapy ecosystem is expected to encourage greater use of standardized cell-culture supplements with defined quality and manufacturing characteristics. National standardization efforts covering ancillary materials used during cell and gene therapy production provide a stronger framework for consistent manufacturing inputs.
BioE3 policy is expected to strengthen domestic bioprocessing capabilities in India through Biofoundries, Biomanufacturing Hubs, and Bio-AI Hubs. Shared infrastructure and scale-up facilities are expected to improve access to advanced bioprocessing technologies and strengthen domestic capabilities across research, process development, and commercialization. This ecosystem is likely to create wider applications for recombinant growth factors and specialized cell-culture components within locally developed cell therapy workflows.
Japan’s biotechnology ecosystem is expected to benefit from continued integration of iPSC-derived cells and disease-specific cellular models into drug discovery and screening activities. AMED supports iPSC research spanning disease modeling, drug discovery, regenerative medicine, and foundational research. Japan’s National Institute of Biomedical Innovation is developing functional cell models and screening systems for drug discovery. These initiatives are expected to increase the use of defined growth factors and cell-culture supplements required for cell differentiation, maintenance, and reproducible model development.
The Europe cell therapy growth factor market is likely to grow at a CAGR of 6.48% during the forecast period.
The regenerative medicine ecosystem is expected to benefit from continued efforts to translate tissue-engineered and cell-based technologies into clinical applications in the UK. MHRA provides dedicated regulatory and scientific-advice pathways for advanced therapy medicinal products, while the UK Life Sciences Sector Plan emphasizes advanced manufacturing, research translation, and health innovation. These initiatives are expected to support the progression of tissue-engineered therapies toward clinical use and create broader applications for characterized growth factors and cell-culture supplements during development and manufacturing.
Medical biotechnology ecosystem in Germany is expected to benefit from stronger connections between biomedical research, technology development, and clinical application. Federal health-research initiatives emphasize faster transfer of research results into healthcare, while biotechnology is positioned as a strategic technology area for strengthening pharmaceutical and industrial competitiveness. This environment is expected to encourage commercialization of cell-based and regenerative medicine platforms, supporting wider use of recombinant growth factors.
The Latin America cell therapy growth factor market is expected to grow at a CAGR of 6.48% during the forecast period. Brazil’s health technology strategy is expected to strengthen domestic development and production of advanced biotechnologies, supported by national policies focused on technological capacity and integration. Anvisa’s established regulatory framework for advanced therapy products covers cell-based, tissue engineering, and gene therapy products, providing a structured pathway for clinical development.
Advanced therapy ecosystem is expected to benefit from increasing localization of cell therapy development in Mexico, supported by COFEPRIS efforts to strengthen regulatory frameworks for innovative biological products and advanced therapies. National pharmaceutical development initiatives also emphasize domestic biotechnology capabilities, while the regulatory pathway for locally manufactured CAR-T therapies provides a foundation for broader clinical translation.
The Middle East & AFrica cell therapy growth factor market is expected to grow at CAGR of 5.94% during the forecast period. UAE’s healthcare transformation agenda is expected to encourage wider adoption of precision cell-based treatments through advanced research infrastructure, specialized healthcare centers, and biotechnology initiatives. National strategies emphasize personalized medicine, and advanced biotechnologies as part of the country’s future healthcare ecosystem.
In South Africa, National research priorities supported through the Department of Science, Technology and Innovation and the South African Medical Research Council emphasize genomics, biotechnology, and advanced biomedical research. Greater integration of genomic characterization with cell-based models is expected to support the use of defined growth factors and specialized culture supplements for patient-derived and disease-specific cellular research.
The cell therapy growth factor market competitive landscape is moderately fragmented, with competition spread across recombinant protein manufacturers, life-science reagent suppliers, cell-culture specialists, and bioprocessing companies. Leading players such as Thermo Fisher Scientific, Merck, Bio-Techne, and STEMCELL Technologies are estimated to collectively account for approximately 30–35% of the global market share.
Established players compete through GMP-grade product availability, recombinant protein consistency, animal-free formulations, and manufacturing scalability. Emerging and specialized players in the cell therapy growth factor market ecosystem compete through application-specific growth-factor combinations, custom formulations, specialized cell-type products, and differentiated stability characteristics, creating a fragmented competitive environment across research and clinical manufacturing applications.
September 2026: HCW Biologics entered an exclusive distribution agreement with Akron Biotech for HCW11-006, a multi-cytokine reagent designed to support production of highly functional CAR-T cells.
May 2026: Pluristyx and Qkine announced a reciprocal distribution agreement pairing clinical-grade iPSC lines with Qkine's animal-free growth factors for iPSC differentiation and cell manufacturing applications.
January 2026: Qkine and Akron Bio announced a strategic partnership to jointly develop and globally supply growth factors and cytokines for stem cell-based therapeutics, including products supporting automated cell therapy manufacturing.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Biologics Contract Manufacturing Market Size, Forecast, 2034
Cryopreservation Cell Lines Market Size, Forecast, Demand, 2034
Antibody Purification Service Market Size, Forecast, Demand, Opportunities, 2034
Red Biotechnology Market Size, Share, Growth, Forecast, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Cell Line Development Services Market Size, Share, 2034
We are featured on:
sales@straitsresearch.com